Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

Enzolytics backs Sagaliam against NIKA's false HIV/AIDS patent claims by CEO Savov, protecting shareholder value and patent rights.

ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the “Company”) stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp (“SAGA”) in its campaign to stop another attempt by NIKA Pharmaceutical and its CEO, Dimtar Savov, falsely claiming rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has, since defaulting on licensing agreements and losses in civil court actions in the US and Bulgarian court systems, erroneously and maliciously asserted claims to ITV-1 in his attempt to mislead the investing public and to harm the shareholder value of SAGA as well as the Company. The exclusive license holder of this intellectual property is Virogentics, Inc., a wholly owned subsidiary of Sagaliam.

Sagaliam press release issued on July 25, 2017: https://finance.yahoo.com/news/sagalium-responds-competitor-false-misleading-204600512.html

Steve Sharabura, Interim CEO of Enzolytics, commented, “I and the Board of Directors are steadfastly aligned with Sagaliam to bring to an end this travesty and the protection of both entities’ shareholder value.”